Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in nonpancreatic neuroendocrine tumors (NET).
Monica M. Mita
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene
Edward M. Wolin
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Tim Meyer
Consultant or Advisory Role - Celgene (U)
Honoraria - Celgene
Research Funding - Celgene
John J. Nemunaitis
Research Funding - Celgene
Emily K. Bergsland
Consultant or Advisory Role - Celgene (U)
Amit Mahipal
Research Funding - Celgene
Lilly Wong
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Xiaoling Wu
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
James Carmichael
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Rajesh Chopra
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Kristen Hege
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Johanna C. Bendell
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene